|
|||||
|
|
Single-dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients. |
|
| Authors: | S C Piscitelli W D Figg B Hahn G Kelly S Thomas R E Walker |
| Abstract: | The pharmacokinetics of thalidomide in nine human immunodeficiency virus-infected patients were studied. Single doses of thalidomide were well absorbed, with mean peak concentrations (+/- standard deviations) of 1.17 +/- 0.21 and 3.47 +/- 1.14 microg/ml in the 100- and 300-mg dosing groups, respectively, and the mean elimination half-life was approximately 6 h. Adverse effects were mild, with drowsiness being reported for seven of nine patients. |
| Keywords: | |